Alaunos Therapeutics, Inc. filed a Form S-3 registration statement with the SEC on November 12, 2026, covering the proposed resale of up to 382,090,789 shares of common stock by selling stockholders connected to two transactions that closed in October 2026.
Key Highlights
- Total shares registered: Up to 382,090,789 shares of common stock are covered by the registration statement on behalf of selling stockholders.
- Merger-related shares: 105,286,000 shares are issuable upon conversion of 105,286 shares of Series B Non-Voting Convertible Preferred Stock, and 33,054,000 shares are issuable upon conversion of 33,054 shares of Series C Non-Voting Convertible Preferred Stock, both tied to the acquisition of Velaris Therapeutics, Inc., which closed on October 13, 2026.
- Private placement shares: 687,789 shares of common stock and 243,063,000 shares issuable upon conversion of 243,063 shares of Series C Preferred Stock were issued in a private placement that closed on October 14, 2026.
- Conversion ratio: Each share of Series B and Series C Preferred Stock may convert into 1,000 shares of common stock, subject to stockholder approval and beneficial ownership limitations.
- Stockholder approvals required: The company disclosed that conversion is conditioned on stockholder approval of both the issuance of common stock upon conversion and an amendment to the certificate of incorporation to increase authorized shares.
- Last reported share price: On November 11, 2026, the last reported sales price for Alaunos common stock was $1.61 per share, according to the filing.
- No proceeds to company: According to the filing, Alaunos will not receive any proceeds from the sale or other disposition of the resale shares by the selling stockholders.
Alaunos Registers Resale Shares Following Velaris Acquisition and October PIPE
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) filed an S-3 registration statement on November 12, 2026, to register up to 382,090,789 shares of common stock for resale by selling stockholders. According to the filing, the shares originate from two separate transactions: the acquisition of Velaris Therapeutics, Inc. and a concurrent private placement, both of which closed in October 2026.
The filing states that the Merger Preferred Shares were issued to former stockholders of Velaris, a Delaware corporation, in connection with the company's asset acquisition, which closed on October 13, 2026. The Private Placement Shares were issued and sold to accredited investors in a PIPE transaction that closed on October 14, 2026. The registered shares consist of 105,286,000 shares tied to Series B Preferred Stock conversions, 33,054,000 shares tied to Series C Preferred Stock conversions from the merger, 687,789 directly issued common shares from the private placement, and 243,063,000 shares tied to Series C Preferred Stock conversions from the private placement.
The filing discloses that conversion of the preferred stock into common stock requires two categories of stockholder approval: approval of the share issuances in accordance with Nasdaq rules, and approval of an amendment to the certificate of incorporation to increase the number of authorized shares of common stock to a sufficient level. The company noted that each share of Series B Preferred Stock may convert at the option of the holder, while each share of Series C Preferred Stock will automatically convert, once the required approvals and beneficial ownership limitations are satisfied. Alaunos is classified in the filing as a non-accelerated filer and a smaller reporting company.
What Was Disclosed
Alaunos Therapeutics filed an S-3 registration statement covering up to 382,090,789 resale shares of common stock on behalf of selling stockholders arising from its October 2026 acquisition of Velaris Therapeutics and a related private placement. The company will not receive proceeds from any resales.



Please wait processing your request...